Jan 03, 2013, 01.26 PM IST
Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.
The company's ANDA for Finasteride tablets has been awarded a 180-day period of marketing exclusivity in the US on January 2.
"The Propecia tablets has US sales of approximately USD 136 million MAT for the most recent 12 months ending October 2012, according to IMS Health," the company said in a release.
At 10:36 hours IST, the stock gained 2.13 percent to Rs 1,877 on the Bombay Stock Exchange.
Dr Reddys Labs stock price
On December 09, 2013, Dr Reddys Laboratories closed at Rs 2449.50, up Rs 27.55, or 1.14 percent. The 52-week high of the share was Rs 2545.00 and the 52-week low was Rs 1720.50.
The company's trailing 12-month (TTM) EPS was at Rs 91.89 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 26.66. The latest book value of the company is Rs 457.59 per share. At current value, the price-to-book value of the company is 5.35.
Tags: Dr Reddy's Laboratories
Action in Dr Reddys Laboratories
Video of the day
Dec 6 2013, 15:02
- in MARKET OUTLOOK
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.